Analytical Data
-
Gene name
IL-31
- Application
-
Alternative Names
IL-31；CRL3；GPL；Interleukin-31 receptor subunit alpha
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6EBC2
-
Expression Region
27-164aa
-
AA Sequence
LPVRLLRPSD DVQKIVEELQ SLSKMLLKDV EEEKGVLVSQ NYTLPCLSPD AQPPNNIHSP AIRAYLKTIR QLDNKSVIDE IIEHLDKLIF QDAPETNISV PTDTHECKRF ILTISQQFSE CMDLALKSLT SGAQQATT
-
Molecular Weight
16 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-31 (IL-31) is a cytokine predominantly produced by Th2 cells and plays a significant role in inflammatory responses and allergic diseases. It is primarily associated with conditions like atopic dermatitis, where high levels of IL-31 are linked to pruritus (itching) and skin inflammation. This cytokine exerts its effects by binding to its receptor, IL-31RA, which forms a heterodimeric complex with Oncostatin M receptor (OSMR). The IL-31 signaling pathway has garnered attention for its distinct role in mediating inflammatory skin conditions and other allergic responses, differentiating it from other Th2 cytokines. Insights into the structure and function of IL-31 have spurred interest in developing therapeutic strategies targeting this pathway. Recombinant IL-31 protein studies are pivotal for understanding its biological functions and the underlying mechanisms of diseases associated with its dysregulation. Investigating the effects of IL-31 at the molecular level will not only enhance our comprehension of its role in the immune system but also facilitate the development of potential interventions for conditions characterized by IL-31 overexpression. By elucidating the intricate relationships between IL-31 and various immune responses, researchers aim to provide novel therapeutic options for patients suffering from IL-31-related inflammatory diseases. The ongoing exploration of IL-31, particularly through recombinant protein technologies, serves as a promising avenue for therapeutic innovation in the treatment of chronic inflammatory and allergic diseases.
